High levels of IGF-1 and FGFR-3 have been found in biopsies of melanoma patients treated with BRAF inhibitors in monotherapy or in combination with MEK inhibitors and IGF-1, and its receptor (IGF-1R) are associated with resistance to MAPK inhibitors [118]. Here, MAP2K7 is linked to melanoma.